92 filings
Page 3 of 5
8-K
pc7fj57c
10 May 21
Mersana Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update
5:00pm
8-K
w8s7q etn6
9 Apr 21
Entry into a Material Definitive Agreement
4:19pm
8-K
rc83 wupgz1w7
11 Mar 21
Mersana Therapeutics Announces Appointment of Allene Diaz to Board of Directors
9:17am
8-K
3e7kpiynotib5gatowl
26 Feb 21
Mersana Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
6:29am
8-K
oqs3gwb
5 Jan 21
Mersana Therapeutics Announces Corporate and Pipeline Updates and 2021 Goals and Anticipated Milestones
9:58am
8-K
9r1eyexf b41
30 Nov 20
Mersana Therapeutics Appoints Arvin Yang, M.D., Ph.D. as Senior Vice President
8:15am
8-K
3i4q0lnv
9 Nov 20
Mersana Therapeutics Announces Third Quarter 2020 Financial Results and Provides Business Update
6:30am
8-K
jtqr9xwsc tk77oco1t
17 Sep 20
Mersana Therapeutics Reports Updated Interim Data from the Ovarian Cancer Cohort of the XMT-1536 Phase 1 Expansion Study
6:30am
8-K
qa5twftz
3 Sep 20
Entry into a Material Definitive Agreement
6:36am
8-K
9p8e2a1w5n07mjzwv4oa
7 Aug 20
Mersana Therapeutics Announces Second Quarter 2020 Financial Results and Provides Business Update
6:30am
8-K
fhv 0c3025dy
16 Jun 20
Submission of Matters to a Vote of Security Holders
5:20pm
8-K
j4x2wl n6juchf
1 Jun 20
Entry into a Material Definitive Agreement
5:22pm
8-K
4h5qig 0bt
27 May 20
Mersana Therapeutics Reports Positive Interim Data from the Expansion Portion of the XMT-1536 Phase 1 Study
6:30am
8-K
w8p3yjf30ip8squj
14 May 20
Mersana Therapeutics Announces Initiation of XMT-1592 Phase 1 Dose
4:15pm
8-K
b1nyfiel9
8 May 20
Mersana Therapeutics Announces First Quarter 2020 Financial Results and Provides Business Update
6:31am
8-K
q7j4wt0io
15 Apr 20
Mersana Therapeutics Announces Appointment of Martin H. Huber, M.D., to Board of Directors
8:15am
8-K
1les 1srm
8 Apr 20
Other Events
8:30am
8-K
na9cepf66iwn8abs6
30 Mar 20
Mersana Therapeutics Reports Updated Data from the XMT-1536 Phase 1 Dose Escalation Study
4:15pm
8-K
j6c7z180itofjpdxd4
20 Mar 20
Mersana Therapeutics to Report Updated Data from the XMT-1536 Phase 1 Dose
9:38am
8-K
lvwa zid48q2rx
16 Mar 20
Entry into a Material Definitive Agreement
8:00am